Literature DB >> 3793263

Non-contraceptive oestrogens and the risk of breast cancer in women.

C La Vecchia, A Decarli, F Parazzini, A Gentile, C Liberati, S Franceschi.   

Abstract

The relationship between use of non-contraceptive oestrogens and risk of breast cancer was investigated using data from a hospital-based case-control study from Northern Italy. This study covered 1,108 patients with histologically confirmed breast cancers and 1,281 control subjects with a large spectrum of acute conditions unrelated to any of the known or suspected risk factors for breast cancer. Compared with "never-users", the age-adjusted relative risk for "ever-users" was 1.93 (95% confidence interval = 1.35-2.75). The risk increased with duration of use (relative risk = 2.08 for over 2 years), but was unrelated to time elapsed since first or last use. Allowance for a large number of identified potential confounding factors, including indicators of socio-economic status and the major determinants of breast cancer risk, failed to account for the observed association (multivariate relative risk = 1.84 for ever use and 2.04 for greater than 2 year use). Possible explanations for these findings and for their apparent discrepancy with some American data are discussed in terms of different baseline incidence of breast cancer in the two populations, and hence of potential baseline differences in availability of endogenous serum oestrogens. Nonetheless, the results of this study should be interpreted cautiously and viewed as a further contribution to a topic still open to debate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3793263     DOI: 10.1002/ijc.2910380612

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Noncontraceptive hormone use and risk of breast cancer.

Authors:  C P Yang; J R Daling; P R Band; R P Gallagher; E White; N S Weiss
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

Review 2.  Hormone replacement therapy and breast cancer. A review of current knowledge.

Authors:  L Bergkvist; I Persson
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

3.  Lifetime menstrual activity--indicator of breast cancer risk.

Authors:  M Rautalahti; D Albanes; J Virtamo; J Palmgren; J Haukka; O P Heinonen
Journal:  Eur J Epidemiol       Date:  1993-01       Impact factor: 8.082

Review 4.  A risk-benefit appraisal of transdermal estradiol therapy.

Authors:  A Cheang; R Sitruk-Ware; W H Utian
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 5.  Familial breast cancer.

Authors:  D G Evans; I S Fentiman; K McPherson; D Asbury; B A Ponder; A Howell
Journal:  BMJ       Date:  1994-01-15

Review 6.  Estrogen therapy during menopause. Practical treatment recommendations.

Authors:  R Sitruk-Ware
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 7.  Estrogen replacement therapy in women at increased risk for breast cancer.

Authors:  R Vassilopoulou-Sellin
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

8.  The application of age, period and cohort models to predict Swiss cancer mortality.

Authors:  E Negri; C La Vecchia; F Levi; A Randriamiharisoa; A Decarli; P Boyle
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 9.  Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.

Authors:  J A Balfour; D McTavish
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

Review 10.  Estrogen replacement therapy (ERT) in high-risk cancer patients.

Authors:  K A Hutchinson-Williams; J N Gutmann
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.